Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00037622
Status:
TERMINATED
Last Update Posted:
2009-08-19
First Post:
2002-05-17
Brief Title:
Safety and Antiviral Study of ACH-126 443 Beta-L-Fd4C in the Treatment of Adults With Chronic Hepatitis B Infection
Sponsor:
Alexion Pharmaceuticals Inc
Organization:
Alexion Pharmaceuticals Inc
Study Overview
Official Title:
An Open-Label Treatment Protocol to Provide Continued ACH-126443 to Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection
Status:
TERMINATED
Status Verified Date:
2009-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Safety concerns from other studies
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety and antiviral HBV activity of ACH-126443 beta-L-Fd4C in the treatment of Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection
Detailed Description:
Evaluation of safety and antiviral activity of the 5mg dose of ACH-126443 for up to three months of treatment in the population described
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None